Agilent Technologies (NYSE:A) Price Target Raised to $90.00

Agilent Technologies (NYSE:A) had its price target increased by Oppenheimer from $67.00 to $90.00 in a report published on Tuesday morning, Marketbeat.com reports. Oppenheimer currently has an outperform rating on the medical research company’s stock.

Other equities analysts have also recently issued reports about the stock. Wolfe Research began coverage on shares of Agilent Technologies in a research report on Wednesday, December 13th. They set an outperform rating and a $140.00 price objective for the company. UBS Group lifted their price objective on shares of Agilent Technologies from $130.00 to $155.00 and gave the stock a neutral rating in a research report on Wednesday, February 28th. Citigroup lifted their price objective on shares of Agilent Technologies from $130.00 to $145.00 and gave the stock a neutral rating in a research report on Wednesday, February 28th. StockNews.com raised shares of Agilent Technologies from a hold rating to a buy rating in a research report on Tuesday, December 19th. Finally, JPMorgan Chase & Co. lifted their target price on Agilent Technologies from $140.00 to $165.00 and gave the stock an overweight rating in a report on Wednesday, December 20th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have given a buy rating to the company. According to MarketBeat, Agilent Technologies currently has an average rating of Moderate Buy and a consensus price target of $138.29.

Agilent Technologies Price Performance

NYSE:A opened at $145.46 on Tuesday. Agilent Technologies has a 1-year low of $96.80 and a 1-year high of $151.58. The company has a current ratio of 2.68, a quick ratio of 2.04 and a debt-to-equity ratio of 0.41. The firm has a fifty day simple moving average of $137.98 and a 200 day simple moving average of $126.28. The stock has a market capitalization of $42.63 billion, a PE ratio of 34.63, a P/E/G ratio of 4.37 and a beta of 1.11.

Agilent Technologies (NYSE:A) last released its earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.07. Agilent Technologies had a net margin of 18.35% and a return on equity of 27.09%. The business had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.59 billion. During the same period last year, the business earned $1.37 earnings per share. The firm’s revenue was down 5.5% on a year-over-year basis. On average, research analysts expect that Agilent Technologies will post 5.51 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 24th. Investors of record on Tuesday, April 2nd will be paid a $0.236 dividend. This represents a $0.94 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date is Monday, April 1st. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.38%.

Insiders Place Their Bets

In other news, Director Heidi Fields sold 1,658 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total transaction of $239,315.72. Following the sale, the director now directly owns 54,976 shares in the company, valued at $7,935,235.84. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, Director Heidi Fields sold 1,658 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total transaction of $239,315.72. Following the sale, the director now directly owns 54,976 shares in the company, valued at $7,935,235.84. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Philip Binns sold 2,827 shares of the business’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $147.54, for a total value of $417,095.58. Following the sale, the senior vice president now owns 9,997 shares in the company, valued at $1,474,957.38. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 61,610 shares of company stock valued at $9,220,333.

Institutional Trading of Agilent Technologies

Several institutional investors have recently added to or reduced their stakes in the stock. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its position in Agilent Technologies by 3.2% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 2,421 shares of the medical research company’s stock valued at $337,000 after buying an additional 75 shares during the last quarter. Carmel Capital Partners LLC grew its stake in Agilent Technologies by 1.2% in the 4th quarter. Carmel Capital Partners LLC now owns 6,709 shares of the medical research company’s stock valued at $933,000 after purchasing an additional 78 shares during the period. Monumental Financial Group Inc. grew its stake in Agilent Technologies by 0.9% in the 4th quarter. Monumental Financial Group Inc. now owns 9,493 shares of the medical research company’s stock valued at $1,320,000 after purchasing an additional 89 shares during the period. Buckingham Strategic Wealth LLC grew its stake in Agilent Technologies by 1.1% in the 4th quarter. Buckingham Strategic Wealth LLC now owns 8,288 shares of the medical research company’s stock valued at $1,152,000 after purchasing an additional 91 shares during the period. Finally, Kepos Capital LP grew its stake in Agilent Technologies by 3.5% in the 3rd quarter. Kepos Capital LP now owns 2,775 shares of the medical research company’s stock valued at $310,000 after purchasing an additional 93 shares during the period.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.